← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Filius Bart
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0002115417
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 2
- Purchases · 24M
- 2
- Average purchase
- $244.5K
- Median purchase
- $244.5K
- Gross purchase value
- $489.0K
Companies: ProQR Therapeutics N.V.
2 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-21 | ProQR Therapeutics N.V. | PRQR | Director | $258.0K | Open filing |
| 2026-06-30 | ProQR Therapeutics N.V. | PRQR | Director | $231.0K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ $100k
- 2/2
- Cluster buying · 15D
- 1/2
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.